Search Results

Celanese Announces Commercial Launch of Glaukos’ iDose ® TR (Travoprost Intracameral Implant) Using Celanese’s VitalDose ® Ethylene Vinyl Acetate (EVA).

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).

Celanese Corporation announced that it has entered into an agreement with the Population Council to supply its VitalDose® Drug Delivery Platform for use in a new Multipurpose Prevention Technology Intravaginal Ring.

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Alessa Therapeutics announced their collaboration for developing a new oncology drug product leveraging Alessa’s expertise on sustained localized drug delivery and the Celanese VitalDose® EVA drug delivery platform.

Celanese Corporation (NYSE: CE) today announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR, a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye.

Celanese Corporation announced an investment in expanded capabilities to meet high global demand for pharmaceutical-grade polymers used in the development of implants and inserts for sustained-release drug delivery.

Celanese Corporation, a global chemical and specialty materials company, announced receipt of a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.

Ovensa Inc. and Celanese Corporation announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the market.

Celanese Corporation, a global chemical and specialty materials company, announced an expansion of its Florence, Kentucky research and development center with the addition of a Pharmaceutical Drug Delivery Feasibility Lab.